Navigation Links
DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco
Date:3/1/2010

CLEVELAND, March 1 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the Drug Information Association's 22nd Annual EuroMeeting to be held at the Grimaldi Forum in Monaco on March 8-10.

Attendees are invited to visit Bill Coates, Vice President of Sales, and Martijn Princen, Director of European Sales, at Booth 72 to see how DATATRAK ONE™ provides a singular vision for the product and service delivery of all your clinical trial needs. Interested parties may also schedule a personal demonstration during the show by sending an email request to martijn.princen@datatrak.net.

About DIA Europe.

DIA's Annual EuroMeeting is the largest event of its kind in Europe, attracting more than 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organizations, academic research centers, regulatory agencies, health ministries, patient organizations and trade associations. The event will host more than 350 speakers and 250 exhibitors. For more information on the 22nd Annual EuroMeeting, please see http://www.diahome.org.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the appropriate regulatory agency, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Back to top

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv
2. DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
3. DATATRAK International, Inc. Announces Year-End Backlog
4. DATATRAK Signs Five-Year Registry Study
5. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
6. PFC Pharma Joins DATATRAKs CRO Connect Program
7. DATATRAK Signs 6 Year Study with New Device Client
8. DATATRAK to Present at 2009 SCDM Annual Conference
9. DATATRAK eClinical(TM) Supports Multifaceted Studies
10. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
11. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... 18, 2017  Astute Medical, Inc., developer of biomarkers ... be presented at the 2017 National Kidney Foundation (NKF) ... continues through April 22. Physicians will present data on ... assess risk for acute kidney injury (AKI) during the ... Elevated levels of TIMP-2 and IGFBP-7 ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):